HRP20210999T1 - Derivati tirozina i pripravci koji ih sadrže - Google Patents

Derivati tirozina i pripravci koji ih sadrže Download PDF

Info

Publication number
HRP20210999T1
HRP20210999T1 HRP20210999TT HRP20210999T HRP20210999T1 HR P20210999 T1 HRP20210999 T1 HR P20210999T1 HR P20210999T T HRP20210999T T HR P20210999TT HR P20210999 T HRP20210999 T HR P20210999T HR P20210999 T1 HRP20210999 T1 HR P20210999T1
Authority
HR
Croatia
Prior art keywords
tyrosine
methyl
amino
propanoate
chloro
Prior art date
Application number
HRP20210999TT
Other languages
English (en)
Inventor
Steven Hoffman
Original Assignee
Tyme, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme, Inc. filed Critical Tyme, Inc.
Publication of HRP20210999T1 publication Critical patent/HRP20210999T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (13)

1. Postupak, naznačen time, da obuhvaća: ⋅ pribavljanje derivata tirozina, čvrstog materijala u česticama, i melanina; i ⋅ primjenu akceleracijske sile na navedeni derivat tirozina, navedeni čvrsti materijal u česticama, i navedeni melanin u vremenskom periodu i pod uvjetima koji su učinkoviti tako, da uzrokuju, da najmanje jedan od navedenog derivata tirozina i navedenog čvrstoga materijala u česticama potpuno opkoljava ili djelomično opkoljava drugi od navedenog derivata tirozina i navedenog čvrstog materijala u česticama.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da se derivat tirozina nalazi u svojem L-obliku, svojem D-obliku, ili u racemičnom obliku.
3. Postupak prema patentnom zahtjevu 1, naznačen time, da je derivat tirozina jedan ili više od: metil (2R)-2-amino-3-(2-kloro-4-hidroksifenil)propanoat, D-tirozin etilester hidroklorid, metil (2R)-2-amino-3-(2,6-dikloro-3,4-dimetoksifenil)propanoat, H-D-Tyr(TBU)-alilester HCl, metil (2R)-2-amino-3-(3-kloro-4,5-dimetoksifenil)propanoat, metil (2R)-2-amino-3-(2-kloro-3-hidroksi-4-metoksi-fenil)propanoat, metil (2R)-2-amino-3-(4-[(2-kloro-6-fluorofenil)metoksi]fenil)propanoat, metil (2R)-2-amino-3-(2-kloro-3,4-dimetoksifenil)propanoat, metil (2R)-2-amino-3-(3-kloro-5-fluoro-4-hidroksifenil)propanoat, dietil 2-(acetilamino)-2-(4-[(2-kloro-6-fluorobenzil)oksi]benzil malonat, metil (2R)-2-amino-3-(3-kloro-4-metoksifenil)propanoat, metil (2R)-2-amino-3-(3-kloro-4-hidroksi-5-metoksifenil)propanoat, metil (2R)-2-amino-3-(2,6-dikloro-3-hidroksi-4-metoksifenil)propanoat, metil (2R)-2-amino-3-(3-kloro-4-hidroksifenil)propanoat, H-DL-Tyr-OMe HCl, H-3,5-dijodo-Tyr-OMe HCl, H-D-3,5-dijodo-Tyr-OMe HCl, H-D-Tyr-OMe HCl, D-tirozin metilester hidroklorid, D-tirozin-OMe HCl, metil D-tirozinat hidroklorid, H-D-Tyr-OMe HCl, D-tirozin metilester HCl, H-D-Tyr-OMe HCl, (2R)-2-amino-3-(4-hidroksifenil)propionska kiselina, (2R)-2-amino-3-(4-hidroksifenil)metilester hidroklorid, metil (2R)-2-amino-3-(4-hidroksifenil)propanoat hidroklorid, metil (2R)-2-azanil-3-(4-hidroksifenil)propanoat hidroklorid, 3-kloro-L-tirozin 3-nitro-L-tirozin, 3-nitro-L-tirozin etilester hidroklorid, DL-m-tirozin, DL-o-tirozin, Boc-Tyr(3,5-I2)-OSu, Fmoc-Tyr(3-NO2)-OH, α-metil-L-tirozin, α-metil-D-tirozin, i α-metil-DL-tirozin.
4. Postupak prema patentnom zahtjevu 3, naznačen time, da derivat tirozina je α-metil-L-tirozin, α-metil-D-tirozin, ili α-metil-DL-tirozin u racemičnom obliku.
5. Postupak prema patentnom zahtjevu 1, naznačen time, da je čvrsti materijal u česticama topiv u vodi ili nije topiv u vodi.
6. Postupak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da čvrsti materijal u česticama jest farmaceutski aktivni sastojak ili ga sadrži.
7. Postupak prema patentnom zahtjevu 6, naznačen time, da farmaceutski aktivni sastojak posjeduje terapijsko djelovanje u liječenju raka, gdje primjerice, farmaceutski aktivni sastojak sadrži najmanje jedan od selektivnog modulatora estrogenskog receptora, inhibitora aromataze, inhibitora signalne transdukcije, medikamenta koja modificira funkciju proteina koji reguliraju ekspresiju gena i ostale stanične funkcije, medikamenta koja inducira stanice raka da se podvrgnu apoptozi, i medikamenta koja interferira s angiogenezom, te je on poželjno tamoksifen, toremifen, fulvestrant, anastrozol, eksemestan, letrozol, imatinib mesilat, dasatinib, nilotinib, bosutinib, lapatinib, gefitinib, erlotinib, temzirolimus, everolimus, vandetanib, vemurafenib, krizotinib, vorinostat, romidepsin, beksaroten, alitretinoin, tretinoin, bortezomib, karfilzomib, pralatreksat, sorafenib, sunitinib, pazopanib, regorafenib, kabozantinib, denileukin, diftitoks, ziv-aflibercept, cisplatin, cisplatinum, (cis-diamindikloroplatinum(II)), karboplatin, oksaliplatin, benzil izotiocijanat, acetilkolin, i dihidrotestosteron (DHT).
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da nadalje obuhvaća dodavanje vodikovog peroksida u navedeni derivat tirozina i navedeni čvrsti materijal u česticama nakon primjene spomenute sile na navedeni derivat tirozina i navedeni čvrsti materijal u česticama.
9. Postupak prema patentnom zahtjevu 1, naznačen time, da se spomenuta sila primjenjuje putem doticaja navedenog derivata tirozina i navedenog čvrstog materijala u česticama s najmanje jednim keramičkim elementom.
10. Pripravak, naznačen time, da se proizvodi putem postupka prema bilo kojem od prethodnih patentnih zahtjeva.
11. Pripravak prema definiciji u patentnom zahtjevu 10, naznačen time, da je za uporabu kao lijek.
12. Pripravak prema definiciji u patentnom zahtjevu 10, naznačen time, da je za uporabu kao lijek za liječenje raka.
13. Pripravak za uporabu prema patentnom zahtjevu 11 ili 12, naznačen time, da se pripravak daje oralno, nazalno, supkutano, intravenozno, intramuskularno, transdermalno, vaginalno, rektalno ili u bilo kojoj kombinaciji navedenoga.
HRP20210999TT 2013-10-22 2021-06-24 Derivati tirozina i pripravci koji ih sadrže HRP20210999T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361894279P 2013-10-22 2013-10-22
US14/062,194 US9585841B2 (en) 2013-10-22 2013-10-24 Tyrosine derivatives and compositions comprising them
EP14802529.9A EP3060200B1 (en) 2013-10-22 2014-10-21 Tyrosine derivatives and compositions comprising them
PCT/US2014/061527 WO2015061288A1 (en) 2013-10-22 2014-10-21 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
HRP20210999T1 true HRP20210999T1 (hr) 2021-11-26

Family

ID=52826750

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210999TT HRP20210999T1 (hr) 2013-10-22 2021-06-24 Derivati tirozina i pripravci koji ih sadrže

Country Status (22)

Country Link
US (2) US9585841B2 (hr)
EP (1) EP3060200B1 (hr)
JP (1) JP6684210B2 (hr)
KR (1) KR102292206B1 (hr)
CN (1) CN106232105A (hr)
AU (1) AU2014340263B2 (hr)
CA (1) CA2927980C (hr)
CY (1) CY1124386T1 (hr)
DK (1) DK3060200T3 (hr)
ES (1) ES2879947T3 (hr)
HR (1) HRP20210999T1 (hr)
HU (1) HUE055110T2 (hr)
IL (1) IL245173B (hr)
LT (1) LT3060200T (hr)
MX (1) MX2016005166A (hr)
PH (1) PH12016500729A1 (hr)
PL (1) PL3060200T3 (hr)
PT (1) PT3060200T (hr)
RS (1) RS62216B1 (hr)
SI (1) SI3060200T1 (hr)
WO (1) WO2015061288A1 (hr)
ZA (1) ZA201602770B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
EA201892631A1 (ru) * 2016-05-18 2019-04-30 Тайм, Инк. Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
CN110167580A (zh) * 2016-11-15 2019-08-23 迪美公司 用于治疗癌症的药物组合物和方法
KR20190089191A (ko) * 2016-11-30 2019-07-30 타임, 인크. 티로신 유도체 및 이들을 포함하는 조성물
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018195411A1 (en) * 2017-04-21 2018-10-25 Steven Hoffman Compositions and methods for treating retinopathy
AU2018302248B2 (en) * 2017-07-19 2024-07-25 Hoffman Technologies Llc Compositions for treating stress-related disorders
WO2019059634A1 (ko) * 2017-09-19 2019-03-28 주식회사 스킨큐씨 D-타이로신 또는 이를 포함하는 펩타이드를 포함하는 피부 미백용 조성물
RU2719575C1 (ru) * 2019-02-01 2020-04-21 Общество с ограниченной ответственностью "Центр ранней диагностики нейродегенеративных заболеваний (НДЗ)" Фармацевтическая композиция на основе альфа-метил-п-тирозина и способ ранней диагностики болезни Паркинсона
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
CN114599352A (zh) * 2019-10-15 2022-06-07 迪美公司 用于治疗癌症的α-甲基-DL-酪氨酸烷基酯
EP4090329A2 (en) * 2020-01-17 2022-11-23 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2023128791A1 (ru) * 2021-12-30 2023-07-06 Общество С Ограниченной Ответственностью "Центр Ранней Диагностики Нейродегенеративных Заболеваний" Комбинированное лекарственное средство для ранней диагностики болезни паркинсона

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
CA1108180A (en) 1976-07-21 1981-09-01 Hamao Umezawa Analogs of bestatin
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4389415A (en) 1978-01-24 1983-06-21 Merck & Co., Inc. Method of treating hypertension
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US4806360A (en) * 1987-10-23 1989-02-21 Advanced Polymer Systems Synthetic melanin aggregates
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
JPH02286602A (ja) * 1989-04-28 1990-11-26 Nippon Tokushu Noyaku Seizo Kk 徐放性農薬粒剤
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
CA2154750A1 (en) * 1992-11-19 1994-05-26 Lessek J. Wolfram Compositions and methods for temporarily coloring hair using solubilized melanin
EP0687362A1 (en) 1993-03-04 1995-12-20 Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Gov. Of The U.K. Of Great Britain And Northern Ireland Selective binding materials and assays
JP3204510B2 (ja) 1993-04-05 2001-09-04 コンペティティブ テクノロジーズ，インク． 勃起不全の診断および治療
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
CA2405549A1 (en) * 2000-04-03 2001-10-11 Hybridon, Inc. Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcription coupled repair genes
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
JP2005514438A (ja) * 2001-12-21 2005-05-19 ソーン， デイビッド エス． 薬剤の可溶化、安定化、及び運搬のためのオリゴマー及びポリマーの使用
US8620406B2 (en) * 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
EP3075247B1 (en) * 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
EP2455072A1 (en) 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
EP1700598B1 (en) 2005-03-11 2009-05-13 GPC Biotech AG Anti-proliferative combination therapy comprising satraplatin or JM118 and docetaxel
NZ562064A (en) * 2005-04-01 2011-03-31 Intezyne Technologies Inc Polymeric micelles for drug delivery
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
JP2009534381A (ja) 2006-04-19 2009-09-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 細胞画像化および治療のための組成物および方法
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
FR2918990B1 (fr) * 2007-07-20 2012-12-21 Innov Ia Procede de preparation de compositions pulverulentes stables
WO2009054001A1 (en) 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
CA2717117A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
US20110098241A1 (en) 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
KR101078302B1 (ko) * 2008-05-29 2011-10-31 (주)프로넥스 약물전달체
CA2734828C (en) 2008-08-20 2018-07-24 J. Silvio Gutkind Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EA023244B1 (ru) 2009-04-10 2016-05-31 Хаян Ки Способ предотвращения старения клеток
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
JP6034288B2 (ja) * 2010-07-18 2016-11-30 ニーキ ファーマ インコーポレイテッド ルテニウム錯体を用いる併用療法
AU2013209862A1 (en) 2012-01-17 2014-09-04 Tyme, Inc. Pharmaceutical compositions and methods
US9724657B2 (en) * 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
CA2927980C (en) 2022-07-19
KR20160072239A (ko) 2016-06-22
US11058638B2 (en) 2021-07-13
AU2014340263A1 (en) 2016-05-19
ZA201602770B (en) 2017-04-26
EP3060200B1 (en) 2021-05-26
MX2016005166A (es) 2016-12-14
ES2879947T3 (es) 2021-11-23
PL3060200T3 (pl) 2021-10-11
CA2927980A1 (en) 2015-04-30
SI3060200T1 (sl) 2021-11-30
HUE055110T2 (hu) 2021-10-28
US9585841B2 (en) 2017-03-07
LT3060200T (lt) 2021-08-25
CN106232105A (zh) 2016-12-14
DK3060200T3 (da) 2021-07-12
PH12016500729A1 (en) 2016-05-30
US20150112116A1 (en) 2015-04-23
WO2015061288A1 (en) 2015-04-30
JP6684210B2 (ja) 2020-04-22
NZ719457A (en) 2021-02-26
CY1124386T1 (el) 2022-07-22
IL245173A0 (en) 2016-06-30
US20170172924A1 (en) 2017-06-22
EP3060200A1 (en) 2016-08-31
KR102292206B1 (ko) 2021-08-24
PT3060200T (pt) 2021-07-07
AU2014340263B2 (en) 2019-11-21
JP2016534071A (ja) 2016-11-04
IL245173B (en) 2020-10-29
RS62216B1 (sr) 2021-09-30

Similar Documents

Publication Publication Date Title
HRP20210999T1 (hr) Derivati tirozina i pripravci koji ih sadrže
JP2016534071A5 (hr)
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
HRP20050544A2 (en) Solid drug for oral use
WO2012079092A3 (en) Testosterone undecanoate compositions
JP2017518334A5 (hr)
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
EA201201403A1 (ru) Очень низкодозированные твердые пероральные лекарственные формы для гзт
PH12017502416A1 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2015038135A5 (hr)
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
SA521422467B1 (ar) مركبات هالو-آلِّيلامين واستخدامها
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
JP2012523458A5 (hr)
JP2019515033A5 (hr)
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
JP2008247874A (ja) 育毛促進剤
JP2012097034A5 (hr)
AR119805A1 (es) Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso
JP2017530142A5 (hr)
RU2013126798A (ru) Комбинированная терапия дексаметазоном
US20230046078A1 (en) Methods of using substituted flavones for treating bone disorders
RU2014125701A (ru) Фармацевтическая композиция для профилактики или лечения гипертриглицеридемии или вызванных гипертриглицеридемией заболеваний
MA56024A (fr) Procédé de préparation de compositions pharmaceutiques contenant des principes actifs amphiphiles